Evolus Inc. (0K16)
LSE 
Summary
0K16 Chart
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Evolus: The Injectable Platform Is Becoming The Real Moat
Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and recurring revenue. Q2 2026 results showed 21% revenue growth, positive adjusted EBITDA, and raised guidance, with management projecting 2028 revenue of $450M–$500M and EBITDA margins of 13–15%. Evolus trades at a forward EV/Sales of 1.86, a 50% discount to sector median, but requires margin expansion to justify valuation as it transitions from single-product to platform economics.
Evolus Inc. (0K16) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Evolus Inc. ever had a stock split?
Evolus Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | David Moatazedi CEO | LSE Exchange | 30052C107 CUSIP |
| US Country | 353 Employees | - Last Dividend | - Last Split | 8 Feb 2018 IPO Date |
Overview
Evolus, Inc. operates within the performance beauty sector, focusing on the cash-pay aesthetic market across the United States, Canada, and Europe. Since its incorporation in 2012, the company has dedicated itself to offering innovative aesthetic products. With its headquarters in Newport Beach, California, Evolus has carved out a niche in the competitive beauty industry by providing alternatives for temporary improvement in the appearance of facial lines and wrinkles.
Products and Services
- Jeuveau: This proprietary formulation of 900 kilodalton purified botulinum toxin type A is specifically designed for the temporary improvement of moderate to severe glabellar lines in adults, catering to the demand for non-surgical cosmetic procedures.
- Dermal Filler Products:
- Estyme: A dermal filler product offered by Evolus, aiming to address various aesthetic concerns by smoothing out wrinkles and adding volume to facial structures.
- Evolysse: Another dermal filler in Evolus' portfolio, designed to offer patients aesthetic enhancements and corrections with a focus on natural-looking results.
